Expert consensus on intravesical therapy for non-muscle invasive bladder cancer (2021 edition) / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 1027-1033, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-920984
ABSTRACT
Bladder cancer is one of the common malignant tumors in China, with 75% of bladder cancer being non-muscle invasion with a high recurrence rate after surgery. Intravesical therapy is an useful methods to either directly kill tumor cells by infusing cytotoxic drugs into the bladder or directly or indirectly induce local immune responses of the body through infusing immune agents, such as bacillus calmette guerin, and thus reduce the risk of tumor recurrence and progression. In 2019, the Urological Chinese Oncology Group issued the "Expert consensus on intravesical therapy on non-muscle invasive bladder cancer" . Recently, great progress in the clinical diagnosis and treatment of non-muscle invasive bladder cancer has been achieved domestically and abroad, including the risk assessment of non-muscle invasive bladder cancer, the therapeutic choice of intravesical drugs, the adverse reactions and treatment experience of intravesical therapy, and clinical research on new types of intravesical drugs. This consensus is made according to domestic and overseas evidence-based medicine in combination with current clinical practice and experience of intravesical therapy for non-muscle invasive bladder cancer in China. It is an update of the 2019 expert consensus, with the wish to provide a guidance for domestic clinical standardized intravesical therapy for non-muscle invasive bladder cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Urinary Bladder Neoplasms
/
Administration, Intravesical
/
Adjuvants, Immunologic
/
Consensus
/
Neoplasm Invasiveness
/
Neoplasm Recurrence, Local
Type of study:
Practice guideline
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS